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Abstract: The development of vaccines is one of the most significant medical accomplishments which
has helped to eradicate a large number of diseases. It has undergone an evolutionary process from
live attenuated pathogen vaccine to killed whole organisms or inactivated toxins (toxoids), each
of them having its own advantages and disadvantages. The crucial parameters in vaccination are
the generation of memory response and protection against infection, while an important aspect is
the effective delivery of antigen in an intelligent manner to evoke a robust immune response. In
this regard, nanotechnology is greatly contributing to developing efficient vaccine adjuvants and
delivery systems. These can protect the encapsulated antigen from the host’s in-vivo environment
and releasing it in a sustained manner to induce a long-lasting immunostimulatory effect. In view of
this, the present review article summarizes nanoscale-based adjuvants and delivery vehicles such
as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid
nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles,
colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin
receptors and toll-like receptors.
Keywords: nanotechnology; nanocarriers; adjuvants; vaccines; vaccine delivery systems; viral
vectors; non-viral vectors
1. Introduction and Historical Background
Nanotechnology used for the diagnosis, monitoring, control, prevention and treatment
of disease is referred to as “nanomedicine” [1]. Nanomedicine is a vast area that includes
the use of nanoscale materials for a wide spectrum of applications from sensing, laboratory
diagnostics (e.g., quantum dots) [2] to silicon microchips for drug release, micro-machined
hollow needles (e.g., nanoscale microfabrication-based devices), etc. In recent years, an
interesting application of nanotechnology in vaccine delivery has been exploited [3,4].
The development of vaccines is one of the most successful interventions that has
helped to decimate many diseases. The Centre for Disease Control and Prevention (CDC)
defines a vaccine as a product that stimulates a person’s immune system to produce immu-
nity to a specific disease, protecting the person from that disease [5]. Vaccines stimulate the
host’s immune system to recognize, destroy and remember the microbe and fight against
the same microbial infection in the future. The development of vaccines has helped to
completely eradicate certain diseases such as smallpox globally [6] and polio in many
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parts of the world (except Afghanistan and Pakistan where wild poliovirus transmission is
reported) [7,8], whereas millions of death and disabilities due to diphtheria, measles, per-
tussis, poliomyelitis, tetanus, and tuberculosis have been prevented since the establishment
of the Expanded Programme on Immunization (EPI) by WHO in 1974 [9]. Other diseases
like influenza and infections due to hepatitis B virus (HBV) and pneumococci are partially
controlled by vaccines [9]. Vaccine development is an extraordinary journey, which started
from live-attenuated pathogen vaccine to killed whole organisms or inactivated toxins
(toxoids) and most recent r-DNA and subunit vaccines, each of them possesses some bene-
fits and shortcomings [10]. Since a live-attenuated vaccine introduces an actual pathogen
to the host, it represents an exact simulation of the immune response leading to life-long
immunity with just one or two doses. However, such vaccines may not be suitable for
administration to immunocompromised patients due to risks associated with them. The
risk, in this case, is due to the fact that a person who receives live-attenuated vaccine may
occasionally cause transmission of vaccine strain to others (particularly a family member or
healthcare worker who provide care to immunocompromised patients) [11]. Furthermore,
recombinant DNA vaccines, subunit vaccines and conjugate vaccines have become more
attractive due to their safety (as unlike live-attenuated vaccines they cannot revert back to
a virulent form) and feasibility to produce large quantities of antigen from recombinant
methods (i.e., it is easy to scale up for mass production) [12]. However, these vaccines
generate a weak immune response due to the use of only a specific part of the whole
organism, while the basic requirement of a potential vaccine is that it should produce a
sufficient immunogenic response to provide effective protection to a host with minimum
side effects. In this context, adjuvants and delivery systems are often necessary to deliver
antigen in a proper manner and to provoke a robust immune response.
Adjuvants are substances that, when used in combination with vaccine antigens,
induce a stronger and more efficacious response to the vaccine as compared to that in-
duced by the vaccine alone [13]. The addition of adjuvants to vaccines has been used
to (i) enhance the immunogenicity of antigens; (ii) reduce the amount of antigen or the
number of immunizations needed for protective immunity; (iii) improve the efficacy of
vaccines in newborns, the elderly or immuno-compromised persons [14]. Broadly, adju-
vants have been grouped into two classes, “immunostimulatory adjuvant” and “vaccine
delivery systems”. Immunostimulatory adjuvants (immunopotentiators) are derived from
pathogen representing pathogen-associated molecular patterns (PAMP) (e.g., lipopolysac-
charides (LPS), monophosphoryl lipid (MPL), cytosine phosphoguanine deoxynucleoties
(CpG DNA)) and initiate innate immunity directly (through cytokines) or through pattern
recognition receptors (PRRs), whereas delivery systems concentrate and display antigens,
target vaccine antigens to antigen-presenting cells (APCs) and help co-localize antigens
and immunopotentiators. For many years, Alum (aluminum hydroxide or aluminum
phosphate gels) has been used as an adjuvant in several licensed vaccines, which elimi-
nates many cytotoxic properties of Incomplete Freund’s adjuvant (IFA) [9,15]. However,
it suffers from drawbacks like instability to freezing and drying, inconsistent and weak
humoral immunity and certain safety concerns which makes it somewhat inefficient im-
munostimulatory [16]. In this regard, delivery systems are greatly contributing to the
development of efficient vaccine adjuvants which acts by facilitating the antigen uptake
by APCs or by elevating the influx of APCs. One advantage of delivering vaccines in
particulate formulations is the ability to protect the antigens from proteolytic breakdown
thereby enhancing vaccine uptake by the cells [17]. Immunopotentiators, e.g., PRRs may
be employed along with the delivery system as they are capable of recognizing molecules
frequently present in pathogens and help generate a robust immune response. Thus, the
delivery system protects the encapsulated antigen from the host’s in-vivo environment
and releases it in a sustained manner to induce a long-lasting target specific immune
response, while immunostimulatory adjuvants (PRRs) provides a stimulatory amount of
linked PRR ligand and enhanced uptake of linked antigen for its effective and preferential
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presentation to APC. This combined approach certainly provides prolong antigen delivery
with increased immunogenicity.
Advanced immunological research has revealed several mechanisms by which vac-
cine adjuvants and delivery vehicles elicit humoral and cellular immunity (Figure 1) [9].
This may include a combination of one or more of the several mechanisms such as depot
formation, upregulation of cytokine and chemokine, immune cell recruitment at the site
of injection, enhanced antigen uptake and presentation to the APCs and surface and in-
tracellular expression of PRRs, activation of inflammasomes, activation and maturation
of APCs (upregulation of expression of major histocompatibility complex (MHC) and
co-stimulatory molecules), migration of matured APC to draining lymph node and im-
munomodulation through induction of B cell (antibodies or immunoglobulins) and T cell
(cytotoxic T lymphocyte-CTL) (Table 1) [18,19].
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Figure 1. Representative mechanism of action of adjuvants. (a) After vaccination, depot formation (in some cases), release
of particles and soluble antigen; (b) Secretion of cytokines and chemokines, which are involved in the recruitment of
various immune cells at the injection site thereby formation of immunocompetent environment; (c) Antigen uptake through
various pattern recognition receptors (PRRs), e.g., Toll-like receptor (TLR) which are expressed on surface as well as
intracellularly. These PRRs are recognized and activated by the antigens and adjuvants; (d) Antigen uptake by antigen-
presenting cells (APCs) leads to maturation and activation of immune cells and further processing for presentatio to
major histocompatibility complex (MHC) by upr gulating the expression of MHC; ( ) Activated APCs then migrate to
draining lymph node to interact with lymphocyte; (f ) this leads to immunomodulation by triggering humoral and cellular
immunity [19,20].
The ability of an adjuvant to qualitatively trigger the immune response is of prime
importance, considering the need for vaccines against cancer, chronic infections such
as HIV, Hepatitis C Virus, Tuberculosis, herpes simplex virus (HSV) and severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). An extended comprehension of the
immunobiology of Toll-like receptors (TLRs) and other PRRs, immunoregulatory cells,
and the importance of specific T helper (Th) cell responses in resolving specific diseases,
provides a necessary framework for the continued development and optimization of
vaccines. This review summarizes various nanosized vaccines (viral), adjuvants and
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2. Nanotechnology-Based Vaccines, Vaccine Adjuvants and Delivery Systems
The introduction of nanotechnology for the development of nanocarriers (adjuvants
and delivery systems) in delivering vaccines is one of the most exciting and challenging
applications in medicine. Nanotechnology in this context refers to the nanocarriers on
the nanoscale (i.e., 1–100 nm). Nanocarriers including viral and non-viral vectors have
been studied as potential tools to deliver vaccines as they are expected to elicit a broad
range of immune responses including cell-mediated immunity (CMI). CMI is an immune
response that involves the activation of macrophages and natural killer (NK) cells, the
production of antigen-specific cytotoxic T-lymphocytes (CTL), and the release of various
cytokines in response to an antigen [40]. Activation of the macrophages and NK cells
helps to destroy intracellular pathogens, the release of CTL destroys cells that display
foreign epitopes on their surface and various cytokines are responsible for the regulation
of immune response [40]. Thus, CMI helps in one way or another to destroy the infected
cells or bacteria/virus. In this article, viral vector-based vaccines, adjuvants and non-
viral particles and delivery systems are reviewed due to their widespread application in
vaccine delivery. Nanocarriers offer many advantages, most importantly their capacity to
interact with biological barriers and transport the bioactive molecule without altering its
antigenicity. Moreover, they—(i) present a large amount of antigen to the immune system;
(ii) control/sustain release of the antigen over a prolonged period of time; (iii) limit the
adverse effects associated with adjuvants by restricting their distribution; (iv) provide
stability to antigen by protecting it from degradation, and (v) provide immunomodulation
and/or immunopotentiation, etc. confirming their utility in vaccinology [41,42]. Following
sections deals with the comprehensive overview of viral vectored vaccines, adjuvants and
delivery systems.
2.1. Viral Vectored Vaccines
The concept of viral vectors was introduced by Jackson et al., in 1972 to create re-
combinant DNA from the CV40 virus using genetic engineering [26]. Thereafter, several
viral vectors have been studied and developed for the benefit of mankind [23,24,26,43].
A viral vector is a naturally evolved vehicle (from virus) and a promising tool for the
purpose of introducing genetic material into the host cell for gene delivery and vaccines to
initiate immune responses [26]. Several viral vectors have been discovered to date. Every
viral vector has distinct advantages such as long term gene expression (Adenovirus, retro-
virus, lentivirus), high titer production (vaccinia and adenovirus), infects non-dividing
and dividing cells (lentivirus), high immunogenicity (lentivirus, vaccinia, Sendai virus,
etc.), induction of unique CTL response (adeno), etc., while disadvantages include low
titer production (adeno-associated adenovirus), generation of replication-competent virus
(retrovirus, lentivirus), the potential for tumorigenesis (retrovirus, lentivirus), infects divid-
ing cells only (retrovirus) [44]. In addition, viral vectors present some common advantages
such as stability of the genome, ease of production, cost-effectiveness, cell specificity over
live/attenuated vaccines, ability to deliver multiple immunogenic with efficient expression
and strong immune response [9,25]. It is well known that the presentation of proteins to the
immune system using viral vectors is similar to those occurring in a natural infection cycle
and therefore provides potent induction of cellular and humoral immune responses [19].
Viral vectors have been playing a vital role in the development of vaccines due to their
unique properties such as encapsulation and protection of sensitive compounds, ease
in modification of exterior, their innate biocompatibility and naturally immunogenic etc.
which led to their developments as actively targeted drug delivery systems [41,42]. Vari-
ous types of viral vectors like retrovirus, lentivirus, adenovirus, adeno-associated virus,
herpesvirus, poxvirus, vesicular stomatitis virus, alphavirus, measles virus, poliovirus,
cytomegalovirus, Sendai virus and HBV have been employed in clinical/preclinical trials
due to their ability to induce a robust immune response and enhanced cellular immu-
nity [26,43]. However, they harbor risks such as toxicities, immunoresponses towards viral
antigens or potential viral recombination, large or complex construction, which limit their
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clinical use [26]. Although the use of viral vectors is a promising system for developing
effective and safe vaccines against many diseases, more studies are needed before the ideal
vector is developed and licensed for human use.
Viral vector such as adenovirus [27], modified vaccinia virus Ankara (MVA) [45],
canary pox vector [46], pox virus [47], measles virus [44], herpes simplex virus (HSV) [48],
alpha virus [49] have been pursued for vaccine delivery against various diseases. Among
them, adenovirus and vaccinia virus are the most widely used vectors. They have provided
an excellent delivery platform for many vaccines against influenza [50], tetanus [51],
malaria [52], human immunodeficiency virus (HIV) [53] and COVID-19 [54] for different
routes of administration. Literature reveals that the human adenoviral vectors (Ad26,
Ad35, Ad5, etc.) induced enhanced memory CD8+ T cells and more polyfunctional CD8+
T cells and have been evaluated in clinical trials [55]. Vaccination of Ad26 priming vector
with an MVA boost elicited a strong and durable antibody response to the Ebola virus
antigen [56,57]. Human Ad serotype 5 (Ad5) vector has also been widely investigated
as a gene delivery vector due to its ability to produce high titers [26]. In a study carried
out by Zhu et al., a recombinant Ad5-based vaccine expressing the glycoprotein of Ebola
Zaire Makona variant was evaluated in phase II clinical trials based on the promising
results of previous preclinical and phase I clinical trial. In a preclinical study, non-human
primates immunized with this Ad5 vector-based vaccine showed significant protection
against the Ebola virus suggesting potential application for clinical studies in human
subjects [36]. Further, Phase I clinical trials on healthy Chinese adults showed good safety
and immunogenicity with the induction of specific antibodies and T-cell response within
28 days of one dose of vaccination. Based on the potential results from the phase I clinical
studies, this vaccine was evaluated on a large population from Sierra Leone (severely
affected by Ebola Virus in 2014) [36]. The authors observed a high humoral immune
response of glycoprotein-specific antibodies in phase II clinical trials with a peak at the
28th day after injection of 8 ⇥ 1010 viral particles and of 1.6 ⇥ 1011 viral particles. Authors
followed up this study up to 6 months and no difference in the antibody response was
noted in volunteers after injection of 8 ⇥ 1010 and of 1.6 ⇥ 1011 viral particles [58]. Although
the short durability of vaccine-elicited antibody indicated a prime booster regimen, the
authors recommended the investigation of 8 ⇥ 1010 viral particles in phase III trials [58].
Due to the recent outbreak of COVID-19 caused by SARS-CoV-2, several studies have
been undertaken worldwide to combat SARS-CoV-2. Zhu et al. studied safety, tolerability,
and immunogenicity of Ad5 vectored COVID-19 vaccine expressing the spike glycopro-
tein of SARS-CoV-2 strain. The authors noted a significant increase in the neutralizing
antibodies at day 14, and peak at day 28 after vaccination. They also observed peak re-
sponse of specific T-cell at day 14 and suggested the requirement of further investigation of
Ad vectored COVID-19 vaccine [58]. In other work, Folegatti et al. studied Chimpanzee-
derived adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2
spike protein in phase I/II, single-blind, randomized controlled trial. The authors reported
an acceptable safety profile and increased antibody responses upon homologous boost-
ing leading to induction of both humoral and cellular immune responses. Evaluation of
this candidate vaccine in phase III clinical studies showed promising results [59], further
leading to the development of ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which is
now authorized for human use [60]. In recent years, the chimpanzee-derived adenovirus
vector has been widely investigated in vaccine research and development due to its unique
feature of non-reactivity to pre-existing human adenovirus neutralizing antibodies [61].
Logunov et al. developed a heterologous COVID-19 vaccine consisting of two components,
a recombinant Ad26 vector (rAd26) and a recombinant Ad5 vector (rAd5), both carry-
ing the gene for SARS-CoV-2 spike glycoprotein (rAd26-S and rAd5-S) and evaluated in
phase I/II clinical trials [62]. They also reported a good safety profile with the induction of
strong humoral and cellular immune responses in participants. All these studies indicated
that the adenovirus expresses a foreign gene as antigen/immunogen for the purpose of
vaccine and thus it functions as both carrier and adjuvant. Several other viral vectors
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such as lentiviral [40–42], modified vaccinia virus Ankara (MVA) [43], cytomegalovirus
(CMV) [23], poxvirus [22,24], measles virus [25,45], vesicular stomatitis virus [15,18], HSV
and alphavirus [27] are also under different phases of clinical trials. Lentiviral and inte-
grase defective lentiviral vector has been used widely in the vaccination strategies and
several preclinical and phase I/II studies are currently undergoing [63–65]. In a Phase I/II
clinical trial, Shenzhen Geno-Immune Medical Institute, China has proposed to develop a
universal vaccine and test innovative COVID-19 minigenes engineered based on multiple
viral genes, using an efficient lentiviral vector system (NHP/TYF) to express viral proteins
and immune-modulatory genes to modify artificial APCs and to activate T cells [64].
MVA-vectored HIV-1 vaccine showed induction of modest vector-specific T cell re-
sponses in human subjects with excellent safety [66]. After two decades of preclinical trials,
MVA vaccine vectors have recently been advanced into clinical trials with two Phase I stud-
ies completed HIV-1 [67], Chikungunya virus (CHIKV) [68]) whereas Phase II CHIKV trials
are ongoing in Europe [69]. These preclinical and clinical studies indicate the usefulness of
viral vectors in vaccination and a promise for future development.
2.2. Virus-Like Particles (VLPs) and Virosomes
VLPs are empty, multiprotein, non-replicating and non-infectious structures resem-
bling natural virions, which are prepared spontaneously during in vitro protein expression
by the self-assembly mechanism of viral protein [70]. VLPs are considered a type of sub-
unit vaccine due to the presence of a non-infectious subset of viral components. Another
subunit vaccine (delivery system) similar to VLPs is called virosomes, which contains an
envelope of mono or bilayer phospholipid vesicles to which additional components of
the virus or pathogen/antigen, virus-derived proteins may be attached or inserted [71,72].
VLPs including virosomes exert their effect on APCs and on antigen-specific lymphocytes
via their overall particle structure and individual components [73]. VLPs and virosomes
have attracted researchers because they are structurally and morphologically similar to
infectious viruses, retain the ability of infective viral particles to bind and penetrate the
cell, and stimulate both humoral and cellular immunity. They are also safe and stable
compared to killed/attenuated viral vaccines and soluble antigens [74]. Promising charac-
teristics of VLPs and virosomes resulted in many marketed products (e.g., Hepatitis B virus
(HBV), human papilloma virus, etc. and fruitful studies under different phases of clinical
trials [70,75]. There are three generations of VLP vaccines against HBV. The first genera-
tion includes Heptavax-B, which is a hematogenous HBV vaccine made up of hepatitis
B surface antigen VLP with a diameter of 22 nm. The second generations HBV vaccines
are genetically engineered vaccines based on HBV VLP, namely Recombivax HB (The first
licensed VLP against HBV) (developed by Merck) and (Engerix-B) (developed by Glaxo
SmithKline) which composed of the viral small envelope protein from Saccharomyces cere-
visiae system to stably express Hepatitis B surface antigen (HBsAg), producing particles of
around 20 nm size. These vaccines are widely used today and considered more immuno-
genic than first-generation VLPs. Lastly, third-generation VLP includes Sci-B-Vac which
contains three HBV surface antigens (S, pre-S1 and pre-S2 antigens) [75]. In a single-center
prospective study recruiting 31 HIV-positive adults, the protection rate of Sci-B-Vac vaccine
against HBV was found to be 84% after completion of three doses of vaccine without any
serious side effects [76]. Subsequent studies demonstrated its safety and efficacy in over
500,000 patients. The Sci-B-Vac® is currently approved in Israel and 14 other countries for
commercial use [77], while US FDA has recently accepted its filing of the Biologics License
Application (BLA). Another HBV vaccine called Heplisav-B (Hepatitis B Vaccine (recombi-
nant) adjuvanted) is indicated for the prevention of infection caused by all known subtypes
of hepatitis B virus and approved by the US FDA for use in adults. Heplisav-B is a 20 nm
VLP self-assembly prepared from HBsAg and CpG sequence 1018 as an adjuvant [78]. The
seroprotection rate of Heplisav-B was statistically significant that following Engerix-B at a
95% confidence interval [78]. It is supplied as a sterile solution for intramuscular injection.
In addition, Merck received approval for a VLP vaccine, Gardasil® (a quadrivalent HPV
Pharmaceutics 2021, 13, 455 8 of 29
VLP vaccine) for immunization against human papillomavirus (HPV) and subsequent pre-
vention of cervical cancer and genital warts [79]. Moreover, GlaxoSmithKline introduced
Cervarix® (a bivalent HPV VLP vaccine) vaccine for the prevention of cervical pre-cancer
and cancer associated with oncogenic HPV types 16 and 18 [80]. Currently approved three
prophylactic HPV vaccines in the market viz. Gardasil®, Gardasil-9® (a nonvalent HPV
VLP vaccine), Cervarix® and Cecolin uses L1 major capsid protein, which self-assemble into
VLPs to induce strong and specific anti-L1 VLP immune response, while next generation
vaccines using L2 peptide are under investigation [81]. Primary mechanism of action of
commercial VLP vaccines is to produce antibodies VLP parent virus specific antibodies,
which further neutralize the parent virus to protect against infection.
The first virosome-based vaccine formulation was developed and patented by Berna
Biologics Ltd. Switzerland and it is marketed as Epaxal®. Epaxal® consists of formalin-
inactivated Hepatitis A virus (HAV) (strain RG-SB), which has demonstrated tolerance and
high immunogenicity with 88–97% seroprotection 2 weeks after a single injection. Unlike
other vaccines, this vaccine formulation is devoid of aluminum hydroxide adjuvant sug-
gesting the potential use of virosomes as a vaccine adjuvant delivery system [75,82]. Direct
comparison of Epaxal with aluminum-adsorbed vaccine demonstrated similar immuno-
genicity with fewer local reactions [83]. Similarly, Inflexal® V is another virosome-based
adjuvanted influenza vaccine licensed for all age groups (up from 6 months) that was devel-
oped by Berna Biologics Ltd., Switzerland [9]. Inflexal®V is composed of a haemagglutinin
surface molecule of the influenza virus, which is attached to the lecithin phospholipid
bilayer virosome. The Inflexal® V virosomes are spherical, unilamellar vesicles with a size
of around 150 nm [82]. Mymetics, a US-registered biotechnology company has a pipeline
of potential virosomal vaccines to malaria and influenza that are being tested in clinical tri-
als [84]. Thus, advancements in the VLP and virosome technology have shown promising
characteristics of these carrier systems to carry potential antigens to induce an effective
immune response, which can be seen by already existing products in the market for clinical
application.
2.3. Non-Viral Vectors
Non-viral vectors are often called delivery vehicles and typically consist of DNA (usu-
ally plasmid DNA produced in bacteria) or RNA as an antigen which is delivered to the
target cell to elicit immune response [85]. In addition to nucleic acids, proteins and peptides
antigens delivery by non-viral vectors also shows great potential in vaccine development.
However, the potential drawbacks of endonuclease degradation, lower efficiency and re-
peated doses of naked DNA vaccine have been reduced using delivery vehicles. Therefore,
natural or synthetic materials (lipids, polymers) have been utilized to prepare non-viral
vectors which encapsulate or adsorbs antigen and fuse with the cell membrane to release it
into the cytoplasm of the cell. Vaccination with non-viral vectors presents many advantages
over viral vectors like safety and efficacy (due to absence of viral component), no limit to
DNA insert size, ease in large scale production, low or no-host immunogenicity, protection
of antigens, targeting, long-lasting gene expression and adjuvant effect [86]. However,
certain disadvantages like low transfection efficiency, episomal expression, cellular toxicity,
inflammation due to unmethylated CpG DNA sequences limit their use [26]. Some of the
widely investigated adjuvants and delivery systems such as adjuvants, with appropriate
preclinical and clinical examples, are discussed below.
2.3.1. Nanoemulsion-Based Adjuvants
MF59
MF59 is an oil-in-water (o/w) emulsion composed of squalene (4.3% v/v) (a naturally
occurring substance) and two surfactants, polysorbate 80 (0.5% v/v, Tween 80) and sorbitan
trioleate (0.5% v/v, Span 85) emulsified in citrate buffer leading to the formation of ~160 nm-
sized droplets [87]. An MF59-adjuvanted seasonal influenza vaccine (Fluad®) was the first
MF59 vaccine to be licensed, in 1997. Later, in 2009, an MF59-adjuvanted H1N1 pandemic
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influenza vaccines (Focetria® and Celture®) were licensed and have been distributed to
populations including pregnant women, young children and elderly people [88,89]. Though
MF59 is a superior adjuvant than alum in inducing both antibody and T cell responses for
the influenza vaccine, side-effects such as pain at the injection site and reactogenicity have
been observed in some patients [90]. Despite these common side-effects of vaccines, there
is continued interest by researchers in employing them as adjuvants. Recently, Yang et al.
designed a vaccine consisting of OmpK/Omp22 fusion protein in combination with MF59
to protect against Acinetobacter baumannii infections. Intratracheal immunization along
with two booster doses induced antigen-specific antibodies, lowered bacterial load in
the blood and lung tissues, and controlled blood inflammatory cytokines resulting in a
greater survival rate in BALB/c mice [91]. In another study, Chang et al. administered
intramuscular single immunization of inactivated whole-virion H7N9 influenza vaccine
in a mouse model. The vaccine successfully induced specific immunoglobulins (Ig), IgM
and IgG titers as detected by ELISA suggesting effective protection against the H7N9 virus
after a single dose [92]. These studies show the promise of MF59 as an effective adjuvant.
The chemical structure of muramyl dipeptide (MDP) can be modulated to enhance its
adjuvant activity while limiting its pyrogenic side effects by using oil-in-water emulsion
carriers such as MF59. Murabutide (MB), is a safe derivative of MDP, and is a squalene-
based emulsion adjuvant that interacts with both innate and adaptive immune systems and
induces its effect through activation of NOD2 (Nucleotide-binding oligomerization domain-
containing protein 2) [93]. Kantipakala et al. used MB to formulate a vaccine delivery system
with ovalbumin (OVA) as a model antigen. The MB-based system was rapidly uptaken by
dendritic cells (DCs) and upon in vivo subcutaneous delivery triggered a 32-fold increase
in OVA-specific IgG antibody titers and upregulated interleukins (IL) namely IL-2, IL-12
and interferons (IFN)-  cytokines indicating Th1 (cells stimulate cellular immune response,
participate in the inhibition of macrophage activation and stimulate B cells to produce
IgM, IgG1 [94]) immune response in mice [95]. In another study, Feinen et al. tested the
adjuvanticity of the murabutide and Advax, an adjuvant made from delta inulin, in murine
pulmonary anthrax infection model based on recombinant protective antigen (PA). The
combination induced a robust and enduring B-cell memory response post-aerosol challenge
by Bacillus anthracis Sterne (strain 7702) as reflected by ~4-fold higher anti-PA IgG titers
and 3-fold less inflammation than PA with Alhydrogel in female A/J mice [96].
Montanide™
SEPPIC Inc. (Paris, France) developed highly refined emulsifiers from the mannide
monooleate family in a natural metabolizable oil solution, which were named as Mon-
tanide™ ISA 50V, 51, ISA 206, 720 [97]. Among these, ISA 50V, 51 and 720 are w/o emulsions
while ISA 206 is a water-in-oil-in-water (w/o/w) double emulsion with particle size ranging
between 10–500 nm. Although these adjuvants have been shown to induce a strong immune
response, severe local reactions have limited their use. As per clinical studies, Montanides™
ISA 51 VG and 720 are safe for human use and induce CD4 and CD8 responses [98]. Savoji
et al. formulated HBsAg in Montanide ISA 266 and compared the induction of cellular
and humoral immune response with commercially available HBsAg/Alum HBV vaccine.
In vivo immunization of BALB/c mice showed that the formulation of HBsAg/Montanide
ISA-266 vaccine elevated IgG1 and IgG2a levels, as markers for Th2 (cells stimulate hu-
moral immune response, promotes B cell proliferation and induces antibody production
(IL-4) [99]) and Th1 patterns, than HBsAg/Alum. This confirmed the robust humoral
response and protection from the protease enzyme by HBsAg/Montanide ISA 266 vac-
cine [100]. In another study, Tehrani et al. demonstrated the efficacy of thiol-specific
antioxidant (TSA) antigen against Leishmania major using adjuvant Montanide ISA 70.
In vivo immunization of BALB/c mice and challenge with Leishmania major revealed that
specific IgG1 and IgG2a levels were elevated and vaccine-elicited humoral and cellular im-
mune response [101]. Currently, Montanide™ adjuvanted vaccines, in particular ISA™51,
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against many diseases such as malaria, HIV, and various cancers are under different phases
of clinical trials and have been reviewed in detail by van Doorn et al. [102].
2.3.2. Lipid Nanocarriers
Immunostimulatory Complexes (ISCOMs)
ISCOMs were first described in 1984 by Morein et al. ISCOM adjuvants are particulate
complexes containing protein antigen, saponin adjuvant (Quil A—which is derived from
the bark of the South American Quillaia saponaria Molina tree), cholesterol, and phospho-
lipids [28]. The cholesterol strongly interacts with saponin to form a unique cage-like
particulate structure with a size of 40 nm, which is likely to contribute to the stability of
the adjuvant and also reduces the hemolytic activity of the saponins which is important
for its safety [9]. ISCOM complex traps the protein antigens (typically hydrophobic mem-
brane proteins) through apolar interactions [103]. ISCOMs can bind and penetrate cellular
membranes and helps deliver the immunogen into the cytosol of the target cell leading
to endogenous processing and presentation of the immunogenic peptide via MHC-I for
induction of CD8+ T cells [104]. Thus, ISCOMs represent good vehicles for intracellular
delivery of DNA-based vaccines [105]. Pabreja et al. formulated a pulmonary tubercular
vaccine using Antigen 85 complex (Ag85)-loaded systems such as the ISCOM. Immunolog-
ical outcomes on BALB/c mice with ISCOMs containing Quil A showed a high level of
IgG1 supporting significant development in humoral and cellular immune responses after
pulmonary immunization [106]. Cibulski et al. investigated the immunological activity
of ISCOMs formulated using a saponin derived from Quillaja brasiliensis (QB-90) termed
IQB-90, consisting of cholesterol, phospholipid, and OVA as a model antigen. Subcuta-
neous administration of IQB-90 resulted in strong serum antibody response of specific
IgG1 and IgG2 with effective T-cell proliferation and greater Th1 cytokines responses.
Further, intranasal delivery evoked serum IgG, IgG1, and mucosal IgA responses in distal
systemic sites providing an advantage over traditional ISCOMs based on Quil A [107].
The only concern while employing ISCOMs is the severe toxicity leading to hemolysis or
granulomas [108].
Liposomes
Liposomes are spherical vesicles, with size 500 nm, composed of amphiphilic phos-
pholipids and cholesterol, which self-associate into bilayers with an aqueous interior that
can encapsulate many drug molecules including protein and DNA-based vaccines [33].
In the delivery of vaccines, the antigen (be it peptide, mRNA, or DNA) can either be
adsorbed on the surface of the liposome, loaded in the liposome core, or the lipid bilayer.
A large number of reports have demonstrated immunomodulatory effects such as depot
effect and enhanced ingestion by APCs, of liposomes or suspensions of lipids and/or
phospholipids when administered into the body as a vaccine adjuvant [109,110]. Passive
targeting due to their particulate nature and tendency to interact with macrophages of
the reticuloendothelial system is the likely mechanism of action by which liposomes exert
their adjuvant effect [111]. Few liposome-based vaccine formulations are already approved
(Epaxel, Inflexal, etc.) and several of them are in clinical trials [9,82]. The inclusion of a
cationic compound in the liposomal formulation renders them positive and enhances the in-
teraction with negatively charged cell membranes [112]. Varypataki et al. prepared cationic
liposomes encapsulated with ovalbumin containing the model Cytotoxic T lymphocytes
(CTLs) epitope SIINFEKL and TLR3 ligand. The subcutaneous and intradermal immuniza-
tion of mice concluded that liposomal formulation was successful in inducing a functional
CD8+T cell immune response with 25 fold increase over the free model CTL epitope and
TLR3 ligand [113]. In addition, several studies have used a combination of dimethyl dioc-
tadecyl ammonium (DDA) lipid-based liposomes to enhance immunity against influenza,
chlamydia, erthrocytic-stage malaria and tuberculosis infections [109,114].
Liposomes enable efficient delivery of mRNA and have been extensively used to
deliver both conventional and self-amplifying mRNA against infectious pathogens. Moyo
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et al. utilized a polyethyleneimine (PEI)-based self-amplifying mRNA vaccine encoding
HIV-1 proteins to induce potent T cell responses in BALB/c mice. A single immuniza-
tion induced polyfunctional CD4+ and CD8+ T cell responses that were maintained for
at least 22 weeks post-immunization and controlled HIV-1 infection [115]. Dai et al. de-
veloped polyethylene imine (PEI) incorporated liposomes for the administration of the
lipopeptide-based vaccine containing Group A Streptococcus (GAS J8) epitope (as B cell
epitope) against GAS. Intranasal administration of mice by liposomal vaccine induced sig-
nificant mucosal and systemic immunity by the production of IgA and IgG antibodies [116].
In another study, Huang et al. utilized Pfs230, a malaria transmission-blocking antigen,
along with cobalt-porphyrin-phospholipid (CoPoP) liposomes for the development of a
vaccine-adjuvant platform. In vivo immunization of CD-1 mice with Pfs230C1/CoPoP
elicited IgG antibodies, induced higher IgG2-to-IgG1 and significantly reduced parasite
transmission as compared to other treatment groups of Alum and Montanide ISA720. Fur-
ther, intramuscular administration of New Zealand white female rabbits showed similar
results with Pfs230C1/CoPoP treatment group eliciting antibodies and inhibiting parasite
transmission [117]. The most recent application of liposomes as a drug delivery carrier and
an adjuvant is Moderna’s candidate vaccine mRNA-1273 for COVID-19. It is a liposomal
formulation encapsulated with nucleoside modified mRNA that encodes the SARS-CoV-2
spike (S) glycoprotein, a vital component of viral entry that allows viruses to penetrate
host cells and cause infection [118]. The initial clinical trials demonstrated that the vaccine
induced anti-SARS-CoV-2 immune response in all participants without significant toxic-
ity [54]. The recently concluded Phase III clinical trial of Moderna’s vaccine candidate for
COVID-19 showed 94.1% efficacy in preventing COVID-19 illness without any local or sys-
temic toxicity, after a two-dose vaccination strategy [119]. Another example is a COVID-19
vaccine candidate by Pfizer and BioNTech, BNT162b2, comprising of lipid nanoparticle
and encapsulated nucleoside modified RNA vaccine with encoded membrane-anchored
SARS-CoV-2 spike protein. The two-dose vaccine regimen was shown to be 95% effec-
tive against COVID-19 infections with mild-to-moderate short-term side-effects making it
available for mass vaccination [120]. In December 2020, Moderna’s and Pfizer-BioNTech’s
COVID-19 vaccine received Emergency Use Authorization (EUA) by the US FDA to prevent
coronavirus disease for use in individuals 18 years of age or older [121,122].
Biodegradable Polymeric Nanoparticles
Biodegradable polymeric NPs (PNPs) display interesting features related to the pro-
tection/stabilization of vaccine antigens until they reach the target site. A large number of
polymers exists from which PNPs can be prepared, amongst which widely used polymers
like (poly-(D,L-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), Poly (alkyl cyanoacry-
lalte) (PACA), polyanhydrides and chitosan, etc., are already approved by the FDA for use
in humans (e.g., as sutures, bone implants and screws as well as implants for sustained
drug delivery) [123]. The biodegradable properties of these polymers make them promising
vehicles for the exploration of antigen delivery; however, researchers are still striving for
regulatory approval and these delivery systems have not yet entered into clinical trials
for vaccine application as there are stability and dose optimization issues that need to be
addressed. Depending upon their type, antigens can be either encapsulated or adsorbed
on the surface of NPs. Encapsulation of antigen ensures its protection from the harmful
gastro-intestinal environment, protects from drug degradation in the systemic circulation
(by avoiding phagocytosis and releasing the drug in cytoplasm) and sustained release
over a prolonged period of time, while adsorption of antigen on NPs avoids exposure to
harmful organic solvents or acidic pH during the formulation process [124].
Various preclinical studies have indicated significant induction of antigen-specific
immunity on the administration of PNPs. Polyanhydride-based nanoparticles and chitosan
nanoparticles exhibit adjuvant-like properties by activating APCs and induce both humoral
and cell-mediated immune responses on their own [37]. To investigate the influence of
polyanhydride chemistry on immune response induction, Wafa et al. synthesized different
Pharmaceutics 2021, 13, 455 12 of 29
compositions of polyanhydride copolymers consisting of 1,8-bis-(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)-hexane (CPH), and sebacic anhydride
(SA). The biodegradable nanoparticles with three different compositions of polyanhy-
dride (50:50 CPTEG:CPH, 20:80 CPTEG:CPH, and 20:80 CPH:SA) encapsulating OVA
were administered subcutaneously in C57BL/6J mice. In vivo immunization with 20:80
CPTEG:CPH treatment group induced a high level of CD8+ T lymphocytes, serum titers of
OVA-specific IgG antibodies and longer protection against tumor challenged with an OVA-
expressing thymoma cell line than other treatment groups suggesting role of copolymer
composition in stimulating immune response [38]. Liu et al. demonstrated antigen stability,
antigenicity and release kinetics of MUC4 - 20:80 CPTEG:CPH nanovaccine. In vitro stud-
ies showed sustained release of MUC4  protein with minimal protein degradation and loss
of epitope availability. In vivo immunization of nanovaccine induced MUC4 -specific IgG
immune response by the synergistic effect of MUC4  and 20:80 CTPEG:CPH nanoparticles
whereas unloaded nanoparticles failed to induce effective antibody response [39]. Using
the previously mentioned copolymer composition of 20:80 CPTEG:CPH, Banerjee et al.
formulated a pancreatic nanoparticle vaccine by encapsulating Mucin 4  (MUC4 ), a
glycoprotein overexpressed in pancreatic cancer. Nanovaccine demonstrated significant
increase in the surface expression of MHC I and MHC II, costimulatory molecules (CD80,
CD86), and the secretion of pro-inflammatory cytokines (IFN- , IL-6, and IL-12) in imma-
ture dendritic cells in vitro compared to MUC4  alone or MUC4 /blank nanoparticles.
Further, in vivo immunization of C57BL/6 mice elicited higher IgG2b to IgG1 ratio along
with a pro-inflammatory cytokine profile (IL-6, IL-12/ IL-23p40 and IFN- ) suggesting a
Th1-biased immune response [36]. Ross et al. demonstrated the immunogenicity of the
recombinant H5 hemagglutinin trimer (H53) encapsulated polyanhydride nanoparticles
(PAN) against H5N1 influenza. Subcutaneous immunization consisting of prime and
booster doses of nanovaccine enhanced CD4+T cell immune responses along with the
induction of high neutralizing antibody titers in female BALB/c mice. Further, vaccinated
mice were challenged with low-pathogenic H5N1 viral load and antibody response and
body weight informatics show that the vaccine regimens induced protective immune re-
sponses without any significant difference in survival between naïve mice that were not
challenged and challenged with virus mice treatment groups [125]. Similarly, Thukral
et al. investigated mycobacterium antigens encapsulated PAN for treatment of Johne’s
disease. The mycobacterium antigens are composed of culture filtrate (PAN-Cf) of M.
paratuberculosis in nanovaccine. Female C57BL/6 mice were vaccinated subcutaneously
and PAN-Cf vaccination group indicated induction of triple cytokines (IFN- , IL-2, TNF-↵)
producing CD8+ T cells in vivo. Following the viral challenge on mice post-vaccination,
the continued production of cytokine secreting CD8+T cells in PAN-Cf vaccinated groups
and a significant reduction in bacterial load, compared to animals that received inactivated
vaccine, indicated the development of protective and sustained immunity against Johne’s
disease [126].
Kunda et al. formulated a dry powder vaccine of PGA-co-PDL (poly(glycerol adipate-
co-!-pentadecalactone)) nanoformulation with particles size of ~150 nm containing antigen
of S. pneumoniae, pneumococcal surface protein A (PspA), to be delivered via the pulmonary
route. In the study, the authors immunized mice and found that mucosal immunization
with formulation targeting the lungs was able to induce local and systemic antibodies,
conferring protection against a Streptococcus strain expressing PspA from the homolo-
gous family 2 [127,128]. Li et al. engineered guanidyl-decorated PEG-PLA NPs (PECG)
with ovalbumin for in vivo immunization. The authors demonstrated robust immune
responses by regulating the secretion of cytokines including IFN-  and tumor necrosis
factor (TNF)-↵ via depot effect [129]. In another study by Gu and co-workers, utilized
immunopotentiator Angelica sinensis polysaccharide (ASP) with PLGA nanoparticles
surface functionalized with PEI and PCV2 antigen together as ASP-PLGA-PEI delivery
system. In vivo immunization of female ICR mice enhanced the antigen uptake, activated
macrophages and lead to the production of IL-1  and IL-12p70 cytokines. Further, ASP-
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PLGA-PEI with adsorbed PCV2 significantly induces PCV2-specific IgG immune response
and cytokines level with mixed Th1/Th2 immune response suggesting an effective vaccine
delivery [130]. Khademi et al. proposed a promising strategy for Mycobacterium tubercu-
losis vaccine consisting of HspX/EsxS-fused protein encapsulated in PLGA and DOTAP
(1,2-dioleoyl-3-trimethylammonium propane). Subcutaneous immunization of BALB/c
mice with the proposed vaccine showed higher levels FN-  and IL-4 cytokines in spleno-
cytes and serum anti-HspX/EsxS IgG1 and IgG2a titers as compared to conventional BCG
(Bacillus Calmette–Guérin) vaccine [131].
The adjuvanticity of poly-"-caprolactone/ chitosan nanoparticles containing HBsAg
and plasmid DNA encoding HBsAg (pRC/CMV-HBs) was investigated by immunization
of C57BL/6 mice. In vivo results showed that the vaccine induced strong anti-HBsAg IgG
titers and antigen-specific IFN-  and IL-17 secretion by spleen cells after subcutaneous
vaccination [132]. In another study, anthrax vaccine was developed by Chaung and co-
workers, consisting of fucoidan-quaternary chitosan nanoparticles and anthrax vaccine
adsorbed (AVA) as adjuvants. In vivo immunization by this anthrax vaccine in A/J mice
demonstrated higher IgG-anti-protective antigen titers compared to CpG ODN plus AVA or
AVA alone. Further, to evaluate protection, the vaccinated mice were subjected to anthrax
lethal toxin challenge and survival studies show a superior survival rate of chitosan plus
AVA vaccination over the other two treatment groups [133]. In order to evaluate the efficacy
of chitosan as adjuvants, El-Sissi et al. developed chitosan nanoparticles (CNP) using ionic
gelation method and loaded them with Rift Valley Fever Virus (RVFV) inactivated antigen
to fabricate RVFV-chitosan nanoparticles-based vaccine (RVFV-CNP). They also utilized
other combinations of RVFV-based vaccines such as RVFV-chitosan (RVFV-CS), RVFV-
Alum, and adjuvant-free RVFV. In vivo vaccination of Swiss albino mice validated the
safety and stimulation of innate and adaptive immunity by upregulating IL-2, IFN-  and
IL-4 in RVFV-CS and RVFV-CNP treatment groups, with later demonstrating superior
efficacy compared to other groups [29]. Biodegradable nanoparticles are advantageous
as they can mimic the priming and boosting effect by modified release and potential for
single-shot vaccines reducing the cost of vaccination.
New classes of materials such as dendrimers, cyclodextrins have also been explored
in vaccine delivery. Dendrimers are highly biocompatible and exhibit predictable biodistri-
bution and cell membrane interacting characteristics due to their size and surface charge.
Their optimal characteristics make them efficient immunostimulating adjuvant that can
increase the efficiency of vaccines [134]. Asgary et al. studied the adjuvanticity of G2 den-
drimer. A nonlinear globular G2 dendrimer comprising citric acid and polyethylene glycol
600 (PEG-600) was synthesized and the adjuvanticity was evaluated in a mice model after
administration with the rabies virus inactivated vaccine. They showed that dendrimer-
based formulations enhanced immune responses, high neutralizing antibodies against
rabies virus, and higher survival rate of mice [135]. Chahal and Khan et al. synthesized
dendrimer molecule encapsulating antigen-expressing replicon mRNAs for adjuvant-free
nanoparticle vaccine. In vivo intramuscular immunization elicited CD8+T cells and an-
tibody responses against various lethal pathogens such as the Ebola virus, H1N1 virus
influenza and Toxoplasma gondii [136].
Non-Biodegradable NPs
Various non-biodegradable materials such as gold [137], carbon [138], silica [139],
quantum dots [140] and polystyrene [141] have been utilized as vaccine delivery sys-
tems and adjuvants. They remain in the tissue for an extended period of time and can
thus present the antigen to tissues with enhanced immunogenicity [9]. In general, this is
achieved by surface functionalization of nanomaterial to target specific cells. Although
non-biodegradable materials facilitate conjugation with different functional groups and
antigens, induce higher cellular and humoral response but often lead to toxicity and
aggregation in tissues requiring further validation of safety [142]. Gold nanoparticles
(GNPs) are efficient adjuvant and delivery vehicles with or without surface functionaliza-
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tion. GNPs have been explored for in vivo delivery of plasmid DNA for HIV treatment.
Xu et al. formulated gold nanorods modified with poly(diallydimethylammoniumchloride)
or polyethyleneimine that significantly promoted cellular and humoral immunity as well
as T-cell proliferation, through activating antigen-presenting cells, when compared to
naked HIV envelope plasmid DNA treatment in vivo [143]. Wang et al. conjugated re-
combinant trimetric influenza hemagglutinin on gold nanoparticles, coupled with TLR-5
agonist flagellin as a particulate adjuvant system. Intranasal vaccination in mice increased
influenza-specific IgA and IgG levels, and led to antigen-specific IFN-  secreting CD4+ cell
proliferation and activated CD8+T cells [35].
Oxidized carbon nanosphere (OCN), a negatively charged carbon nanoparticle was
formulated and investigated for in vitro antigen uptake and ability to generate in vivo
immune response. Subcutaneous immunization of BALB/c mice with OCN and OVA as
a model antigen, demonstrated improved cell-mediated immune response by elevating
antigen-specific CD8+ T cells while localizing in MHC class I compartments [144]. The po-
tential of quantum dots (QDs) as fluorescent nanoparticles for in vitro and in vivo imaging
of DCs is widely explored whereas an antigen-delivery system to enhance DC-mediated
immune responses is being investigated. In a recent study, a group of researchers devel-
oped graphene QDs to access immune and central nervous cells during neuroinflammation
and generate an encephalitogenic Th1 immune response. Intraperitoneal administration
resulted in the inhibition of INF- -expressing T-cells and attenuated autoimmune en-
cephalomyelitis by modulating mitogen-activated protein kinases (MAPK)/Atk signaling
in rats [145].
Calcium Phosphate NPs (CPNPs)
Calcium phosphate has been used for over 30 years to deliver genetic material to
mammalian cells. It has good biocompatibility as it is a naturally occurring, readily ab-
sorbed normal body constituent and thus overcomes safety-related issues [146]. It was used
until the 1980s as an adjuvant in childhood diphtheria–tetanus–pertussis (DTP) vaccine
formulations in France, in the form of calcium phosphate gel or suspension [147]. Sev-
eral preclinical studies have shown that functionalized calcium phosphate nanoparticles
(100–400 nm) are capable of inducing both innate and adaptive immunity by activation of
dendritic cells [148]. BioSante Pharmaceuticals, Inc. demonstrated a better immunostimu-
latory effect of CPNPs in comparison with the commonly used aluminum (alum) adjuvants
for HSV-2 and Epstein–Barr virus (EBV) infections [149]. CPNPs are investigated as an
alternative to aluminum as an adjuvant for many vaccines. In vivo experiments showed
that micrometer-sized CPNP aggregates generated high titer of neutralizing antibody in
BALB/c mice, and showed high protection against HSV-type 2 infection, which is more
potent than aluminum adjuvant [125]. Murcol et al. used CPNP vaccine adjuvant to for-
mulate an inactivated whole virus influenza H1 N1 vaccine as a potential dose-sparing
strategy. In vivo studies in BALB/c mice showed significantly higher hemagglutination
inhibition, virus neutralization and IgG antibody titers than non-adjuvanted vaccines [150].
Kopp et al. fabricated CPNPs with surface conjugated synthetic peptide P1 and P2 against
HSV-1 infections. The P1 and P2 peptides mimic a neutralizing epitope on the HSV-1/2
gB, known to elicit a protective antibody response in mice. The booster immunization of
this vaccine led to the production of cell-to-cell spread inhibiting antibodies and protection
from genital infection and blindness in animal models [151].
Colloidally Stable Nanoparticles
Variety of carbohydrates such as dextran, pullulan and mannose, etc., cannot self-
associate in an aqueous solution due to their water solubility. They can be conjugated to
hydrophobic materials (e.g., cholesterol) to make them amphiphilic. Self-assembling of
these molecules (with and without proteins) leads to the formation of colloidally stable
nanoparticles with a size of 30–40 nm. The size, density and colloidal stability of the
nanoparticles can be controlled by changing the substitution degree of hydrophobes and
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the hydrophobicity. Pullulan is a widely used water-soluble, neutral linear polysaccharide
consisting of ↵–1, 6-linked maltotriose residues. Film-forming properties of Pullulan helps
to entrap biological molecules and its excellent oxygen barrier properties make it stable
with enhanced shelf-life. The mechanism of innate immunity depends on the binding
of polysaccharides to mannose-binding lectins and other C-type lectins of the mannose
receptor family on macrophages and DCs [152]. Various cholesterol-bearing pullulans
with different molecular weights of the parent pullulan and degrees of substitution of the
cholesteryl moiety have been described in the literature [153]. Recently, Nagatomo et al.
prepared cholesteryl pullulan nanoparticles by encapsulating TNF-↵ for nasal delivery of
the H1N1 influenza vaccine. In vivo immunization induced systemic IgG1 and mucosal
IgA responses against a lethal challenge of A/PR/8/34 (H1N1) influenza virus. The
mechanistic studies suggested elevated antigen uptake by DCs and activation of both
B and T cells by expression of inflammation-related genes in nasopharynx lymphoid
tissues [154].
Proteosomes
The proteosome consists of hydrophobic, proteinaceous nanoparticles (~150 nm),
composed of major outer membrane proteins (OMPs) of Neisseria meningitidis [155]. OMPs
have been successfully used in a marketed meningococcal vaccine (Menomune ®, Sanofi
Pasteur) since 1981. Hydrophobic OMP is a good system for the delivery of apolar or
amphiphilic antigens due to noncovalent interaction between the proteosome and antigen
leading to the formation of appropriate complexes [9]. Various human clinical trials have
qualified proteosomes as safe and well-tolerated materials for human use, mainly after
intranasal administration [156]. FluINsure is an intranasal influenza vaccine composed of
inactivated antigens with proteosome adjuvant and showed a good safety profile and in-
duces both humoral and cellular immune responses in adults [157]. Menactra® (Sanofi) is a
quadrivalent conjugate vaccine containing four meningococcal polysaccharides conjugated
to diphtheria toxoid that has also been marketed [158]. Phase I and II clinical studies results
of proteosomes-adjuvanted trivalent inactivated influenza vaccine was safe and tolerable
inducing systemic and mucosal immune responses after intranasal administration [159].
2.3.3. Adjuvants Targeting Pattern Recognition Receptors (PRRs)
The immune system is equipped with receptors known as pattern recognition recep-
tors (PRRs) which are specialized in their recognition to detect pathogens. These receptors
are a vital element of the innate immune system and are mainly expressed by APCs such
as DCs and macrophages, but they are also found in other immune and non-immune
cells. Pathogens such as bacteria, viruses, fungi, and parasites express conserved sets of
molecular patterns referred to as pathogen-associated molecular patterns (PAMPs). APCs
recognize PAMPs through membrane-bound and intracellular receptors known as PRRs.
Interaction between PAMPs and PRRs initiates a cascade of intracellular signaling path-
ways that promotes the production and secretion of pro-inflammatory cytokines such as
type I IFN, TNF-↵, IL-1 and IL-6 and chemokines including IL-8 and RANTES [160]. The
inflammatory responses lead to the migration of mature DCs to lymph nodes and initiate
adaptive immune responses leading to an immunological memory [161,162]. Adjuvants
interact with cellular PRRs and stimulate innate immunity. Presently, numerous PRRs have
been identified, including the TLRs, retinoic acid-inducible gene I (RIG-I)-like receptors
(RLRs), nucleotide-binding oligomerization domain NOD-like receptors (NLRs), C-type
lectin receptors (CLRs) and cytosolic DNA sensors (CDSs). Below, we described widely
investigated PRRs and discuss examples wherein adjuvants targeted PRRs to generate a
robust immune response.
C-Type Lectin Receptors (CLRs)
CLRs are transmembrane receptors that recognize carbohydrate structures represented
by various pathogens. CLR family covers different types of receptors such as DC-SIGN,
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DEC-205, Dectin-1 and 2, and Mincle. They are capable of independently inducing immu-
nity by lysosomal degradation and antigen presentation or deliver powerful signals via
crosstalk to modulate responses triggered by other PRRs [163].
Nanocarriers stimulate CLRs in DCs and can significantly promote internalization and
antigen presentation. For this purpose, mannose-appended pH-responsive nanoliposomes
carrying OVA antigen were formulated to interact with APCs. In vivo immunization of
C57BL/6 mice showed a significant increase in the IL-2, IL-10, IL-12 levels and serum IgG
antibody responses. Mannose anchored liposomes specifically bind to the CLR receptor
on APCs, promote internalization and present antigens (OVA) on MHC class I and II
molecules [164]. Haro and Dyevoich et al. demonstrated that intraperitoneal injection
of TLR and CLR agonist pairing of monophosphoryl lipid A (MPLA) and trehalose-6,60-
dicorynomycolate (TDCM) significantly inhibited tumor growth, ascites development and
mortality associated with peritoneal carcinomatosis and lymphomatosis in mouse mod-
els [165]. Similarly, Phipps et al. formulated TLR and CLR agonist pairing adjuvant and
co-administered with Pneumovax vaccine. The vaccine combination significantly elevated
T-cell independent type-2 antigens and also improved protective efficacy in pneumococcal
respiratory infection mouse models [166]. Recently, researchers examined the crosstalk of
miR-511-3p, encoded within the human MRC1 gene, and CLRs on DCs. The downreg-
ulation of miR-511-3p results in triggering IL-10, IL-4 secretion while suppressing IL-17
with autologous T cells. Further, T-cells polarization and immune response modulation
were controlled through regulating mannose receptors and DC-SIGN expression of the
CLRs [167].
Toll-Like Receptor (TLRs)
Toll-like receptors (TLRs) are integral membrane-bound receptors that are essential for
innate immunity and assist to shape the adaptive immune response. TLRs are triggered by
various PAMPs (includes LPS) and danger-assisted molecular patterns (DAMPs). PAMPs
or DAMPs can engage a variety of TLRs based on their position in the cell and/or made
available after pathogen endocytosis or replication. Owing to their versatile functions,
TLRs are considered the first line of immune defense [168–170]. The number of functional
TLRs can differ in mammals, however, they all have conserved functions of activating in-
flammatory mediators. Humans have 10 TLRs; TLR2 (heterodimerizes with TLR1 or TLR6),
and TLR4/5/10 are present at the cell membrane whereas TLR3/7/8/9 are functionally
localized to endosomes [171]. TLRs contain three domains; an extracellular domain for
sensing the ligand, transmembrane domain to anchor the TLR within membranes, and
Toll/interleukin-1 receptor (TIR) domain to interact with other TIR-containing adaptors to
initiate signaling [172,173].
TLR4 agonist (Monophosphoryl lipid A): Monophosphoryl lipid A (MPLA) is an
agonist of TLR4 receptor developed by GlaxoSmithKline (GSK) for use as a vaccine adju-
vant [174]. It is composed of detoxified lipopolysaccharide (LPS) from Salmonella minnesota
R595. Many studies indicated that the LPS—a major component of the cell wall of Gram-
negative bacteria—is responsible for both adjuvant and toxic effects [175]. The removal of
the phosphate group from the reducing end sugar of the lipid A disaccharide led to 100 to
1000-fold decreased toxicity of the molecule while still retaining the immunostimulating
activity. The resulting derivative having only one phosphate group was named monophos-
phoryl lipid A (MPL®) [174]. Other novel adjuvants and delivery vehicles containing MPL®
(AS04 and AS02A) have also been developed in combination with either aluminum salts
or QS-21 (a purified component of the Quil A) [9]. These combinations have been used
for HSV, HBV, Streptococcus pneumoniae, malaria and human papilloma virus (HPV). AS04
is recently licensed in Europe as a component of an improved vaccine for hepatitis B
(Fendrix) [176]. Tian et al. developed a DNA vaccine against Mycobacterium tuberculosis us-
ing DMT liposomal adjuvant system consisting of dimethyldioctadecylammonium (DDA),
MPLA and trehalose 6,60-dibehenate (TDB). Further, to improve the efficacy of the DMT
vaccine, the authors prepared a complex of DMT and plasmid pCMFO which secretes
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the combination of four multistage antigens (Rv2875, Rv3044, Rv2073c, and Rv0577) of
M. tuberculosis. Immunization of female C57BL/6 followed by M. tuberculosis aerosol in-
fection studies confirmed that the formulated vaccine provides enhanced and persistent
protection by eliciting CFMO-specific IL-2+ T cell responses in vivo [177].
TLR7 and TLR8 agonist: Dowling et al. conjugated Imidazoquinoline, a TLR-8 agonist,
to poly(ethylene glycol)-bl-poly(propylene sulfide) (PEG-bl-PPS) nanocarrier which in-
creased activation and maturation of naïve dendritic cells due to selective endocytosis and
prolonged immunogen by the nanocarrier [178]. Buonsanti et al. introduced a new type of
vaccine based on TLR7 agonist adsorbed to alum (Alum-TLR7) to potentiate the immune
response to glycoconjugate vaccines in humans. They investigated Alum-TLR7 in a mouse
model and results show improved potency of a CRM197-MenC by increasing anti-MenC
antibody titers and serum bactericidal activity against MenC after a single immunization
with a low dose of antigen [179].
TLR9 agonists (CpG oligodeoxynucleotides): Cytosine-phosphorothioate-guanine
oligodeoxynucleotides (CpG ODN) have sequence patterns like those found in bacterial
DNA, activate potent cell-mediated immune responses, and hence are used for the treat-
ment of various diseases [180]. CpG ODN is usually used either as a standalone molecule
or as an adjuvant to alternative therapies. The unmethylated CpG dinucleotide flanked by
two 50 purines and two 30 pyrimidines, present within the bacterial DNA is responsible for
triggering immune responses [181]. CpG ODN are taken up by cells via adsorptive endo-
cytosis and bind to the TLR9 present within the endosomes of B cells and plasmacytoid
dendritic cells [182]. The binding then triggers a cascade of events such as maturation, dif-
ferentiation and proliferation of multiple immune cells (B and T lymphocytes, macrophages,
natural killer cells and monocytes/macrophages that produce IL-1, 6, 12, 18, IFN-  and
TNF-↵) [34,180].
CpG ODN can be conjugated with protein or peptides for nanomedicines and is
broadly divided into two types, covalently bonded or through electrostatic interactions
between CpG ODN and protein/peptide. In the first type, covalently bonding CpG
ODN to an antigen or allergen enables uptake of the adjuvant CpG ODN into the same
antigen-presenting cell that has taken up the antigen. The typical procedure for covalently
bonding a CpG ODN to a protein /peptide is to modify CpG ODN with a thiol group
and protein/peptide with maleimide group and utilize the cross-linking of these groups.
Alternatively, CpG ODN nanomedicines are also used and they are formulated by either
encapsulating CpG ODN in nanomaterials or CpG ODN is surface-bound to nanomaterials.
Goldinger et al. administered MelQbG10, VLP nanocarriers loaded with A-type CpG-
oligonucleotide (CpG-ODN) and in combination with Melan-A/MART-1. In phase IIa
clinical trials, stage III-IV melanoma patients were treated with MelQbG10 and topical
Imiquimod and found to induce strong memory and effector CD8+ T-cell response. Here,
CpG-ODN G10 facilitates T-cell activation and further triggers B-cells via TLR-9 whereas,
Imiquimod activates APCs via TLR-7 [183]. Naito et al. developed the nasal vaccine
consisting of recombinant PcrV adjuvanted CpG ODN against P. aeruginosa pneumonia and
compared it with PcrV/Alum vaccine. Briefly, Institute of Cancer Research (ICR) mice were
classified into treatment groups of PcrV-CpG, PcrV-Alum, PcrV, CpG and Alum and in vivo
studies of IgA and IgG isotope titers supported the superiority of PcrV-CpG vaccinated.
The intratracheal infection with a lethal dose of P. aeruginosa to challenge the vaccinated
mice demonstrated a greater survival rate and disease protection by upregulation of
PcrV-specific IgA titers in mice [184]. Tateishi et al. investigated the protective efficacy
of the A/California/7/2009 (Cal7) spilt vaccine (X179A) along with CpG ODN (G9.1)
after nasal and subcutaneous administration. After in vivo immunization with prime and
booster dose of the vaccine, mice were challenged with Cal7 influenza virus where nasally
delivered vaccine showed better protection and higher recovery rate from an infection
as compared to subcutaneous vaccination. These results show decreased levels of type
I IFN-associated protein and transcription factor-specific mRNA expression suggesting
that vaccine elicits influenza virus-specific mucosal secretory IgA and serum IgG antibody
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responses without inducing inflammatory responses [185]. Nikitezuk et al. studied the
preventive and therapeutic effects on E.G7-OVA tumors of PLGA particles by encapsulating
both OVA and CpG-B ODN. The mice pre-administered with complex PLGA particles
showed inhibition in tumor growth and a higher survival rate than in nontreated mice.
In these mice, the OVA-specific Th1 responses were activated by the complexed PLGA
particles, but there was no increased activation of OVA-specific CTLs, indicating that tumor
growth inhibition could be due to Th1 responses [186]. Zhao et al. demonstrated that carbon
nanotubes (CNT) enhance CpG ODN uptake and potentiate antiglioma immunity in mice.
The CNT-CpG-B complex was formed by surface bonding and when administered into
mice, it showed greater inhibition of tumor growth and a higher survival rate compared
with the free CpG-B ODN administration. This implies that the complexation with CNTs
improves the efficiency of CpG-B ODN uptake and causes activation of CTLs and natural
killer cells [187]. Table 2 below lists various approved and clinically tested vaccines that
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3. Summary
The development of vaccines is one of the most successful interventions that have
helped to reduce the burden of many diseases worldwide. Along with the advancement
in vaccine development, adjuvants have also been of great interest due to their ability
to induce stronger and more efficacious immune responses as compared to the immune
response achieved using vaccines alone. An advanced understanding of clinical immunol-
ogy in the past few decades has greatly influenced the interpretation of the mechanism
of actions of adjuvants and ways to improve their efficacy. The development of vaccines
and adjuvants is further influenced by the introduction of nanotechnology, which con-
tributed in developing efficient vaccine adjuvants and delivery systems. In view of this,
the present review discusses various adjuvants such as viral vectors, virus-like particles
and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegrad-
able and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally sta-
ble nanoparticles, proteosomes; and pattern recognition receptors (PRR) covering c-type
lectin receptors (CLR) and toll-like receptors (TLR) in the area of vaccine development.
It is observed that adjuvants currently used in humans enhance humoral immunity, but
many new adjuvants such as MVA, cationic liposomes, ISCOMs, and biodegradable and
non-biodegradable nanoparticle vectored vaccine have shown to enhance specific T cell
responses in pre-clinical and/or clinical development with excellent safety. The discovery
of immunostimulatory agents like PRRs is also gaining great importance due to their ability
to generate a precise tailor-made protective immune response. Thus, vaccine developers
can now choose suitable adjuvants to achieve beneficial effects of vaccine adjuvants, e.g.,
(i) MF59 for influenza vaccines to attain effectiveness of vaccine at a smaller dose of anti-
gen, (ii) AS04 for hepatitis B vaccine to achieve effectiveness by increasing the speed and
reducing the number of immunizations required, and (iii) MF59 for influenza vaccines
to broaden the range of antibody responses. This shows the diversity of mechanisms of
the well-studied adjuvants may contribute to dealing with challenging diseases such as
HIV, malaria, etc. Since the availability of a plethora of adjuvants, scientists engaged in
the development of vaccines can now choose adjuvants with different properties as per
the requirement. One such recent breakthrough is the approval of a vaccine to combat
SARS-CoV-2 in a short duration of time. Thus, considering the overall development in the
vaccines and adjuvants, eradication of many infectious of global concern will not be too
optimistic to think about.
4. Future Challenges and Perspectives
The application of nanotechnology in vaccinology is rising as the pillar of the health
care system. The enormous growth in this field is changing the world and the way we
live by creating new scientific applications that are smaller, faster, safer, and more reliable,
encompassing new medical treatments by creating new vaccines, adjuvants and vaccine-
delivery techniques. The encouraging results obtained while exploring nano-sized vaccines,
adjuvants and delivery systems have caught the imagination of researchers and vaccine
manufacturers alike. As a result, there has been an explosion of research reports and patents
on adjuvants and delivery systems as adjuvants for vaccine delivery. Further, few nanoscale-
based vaccine delivery products have already made their way to market which includes
viral vectored, virus-like particle, virosomes and MF59 adjuvanted vaccines. Vaccine
delivery systems such as liposomes are also popular among researchers due to their several
advantages some of which include the ability to attach targeting moieties to direct them to
APCs, precise control over particle size, the inclusion of multiple antigens and adjuvants,
and the ability to provide a depot effect. The most recent adjuvants, specifically those that
target PRRs, can be used to tailor the immune response toward Th1/Th2. However, most of
the advances still remain experimental (e.g., polymeric nanoparticles), and the regulatory
agency approval issues are still more critical as it involves the complexities of proving the
safety and efficacy of the vaccine, adjuvants and the vaccine delivery systems owing to
nano-sized particles. In view of this, the FDA, and the European Medicines Evaluation
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Agency (EMEA) have taken the initiative to identify possible scientific and regulatory
challenges. Therefore, if these issues are sorted out, many nanotechnology-based adjuvants
and vaccine delivery systems are expected to serve society. In conclusion, researchers
working in the field of vaccinology have plenty of choices for adjuvants with a variety of
properties based on the type of protective immune response one wants to obtain. Further
advancements will certainly open new avenues in the field of immunization.
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